Delving into the Latest Updates on Garenoxacin Mesilate Hydrate with Synapse

本研究以深圳万乐药业有限公司（生产单位：Toyama Plant，FUJIFILM Toyama Chemical Co.，Ltd.）提供的甲磺酸加诺沙星片（规格：200mg片形：圆形片）为受试制剂，以深圳万乐药业有限公司（生产单位： Toyama Plant，FUJIFILM Toyama Chemical Co.，Ltd.）提供的甲磺酸加诺沙星片（规格：200mg片形：八角形片）为参比制剂，评估受试制剂和参比制剂在空腹和餐后条件下的生物等效性。

[Translation]

In this study, ganofloxacin mesylate tablets (specification: 200 mg, tablet shape: round tablets) provided by Shenzhen Wanle Pharmaceutical Co., Ltd. (manufacturer: Toyama Plant, FUJIFILM Toyama Chemical Co., Ltd.) were used as the test preparation, and ganofloxacin mesylate tablets (specification: 200 mg, tablet shape: octagonal tablets) provided by Shenzhen Wanle Pharmaceutical Co., Ltd. (manufacturer: Toyama Plant, FUJIFILM Toyama Chemical Co., Ltd.) were used as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation under fasting and fed conditions.

Start Date07 Dec 2023

Sponsor / Collaborator

Beijing Yidu Zhengkang Health Technology Co., Ltd.

JPRN-UMIN000016373

/ CompletedNot ApplicableIIT

Clinical efficacy of garenoxacin for treatment of bacterial respiratory infection secondary to chronic respiratory disease - GARIREO study

Start Date30 Jan 2015

Sponsor / Collaborator-

JPRN-jRCT1080222731

/ Unknown statusNot Applicable

Specific post-marketing surveillance of garenoxacin (Geninax) Clinical efficacy and safety of garenoxacin in the treatment of legionella pneumonia

Start Date29 Jan 2015

Sponsor / Collaborator

Toyama Chemical Co., Ltd.

100 Clinical Results associated with Garenoxacin Mesilate Hydrate

Login to view more data

100 Translational Medicine associated with Garenoxacin Mesilate Hydrate

Login to view more data

100 Patents (Medical) associated with Garenoxacin Mesilate Hydrate

Login to view more data

463

Literatures (Medical) associated with Garenoxacin Mesilate Hydrate

05 Jan 2025·Journal of Computational Chemistry

Development of a machine learning‐based target‐specific scoring function for structure‐based binding affinity prediction for human dihydroorotate dehydrogenase inhibitors

Article

Author: He, Zhe ; Zhang, Li ; Tian, Qifeng ; Bao, Wenzhuo ; Feng, Huawei ; Liu, Hongsheng ; Liu, Jinhan ; Hu, Mengfeng ; Meng, Jinhui

AbstractHuman dihydroorotate dehydrogenase (hDHODH) is a flavin mononucleotide‐dependent enzyme that can limit de novo pyrimidine synthesis, making it a therapeutic target for diseases such as autoimmune disorders and cancer. In this study, using the docking structures of complexes generated by AutoDock Vina, we integrate interaction features and ligand features, and employ support vector regression to develop a target‐specific scoring function for hDHODH (TSSF‐hDHODH). The Pearson correlation coefficient values of TSSF‐hDHODH in the cross‐validation and external validation are 0.86 and 0.74, respectively, both of which are far superior to those of classic scoring function AutoDock Vina and random forest (RF) based generic scoring function RF‐Score. TSSF‐hDHODH is further used for the virtual screening of potential inhibitors in the FDA‐Approved & Pharmacopeia Drug Library. In conjunction with the results from molecular dynamics simulations, crizotinib is identified as a candidate for subsequent structural optimization. This study can be useful for the discovery of hDHODH inhibitors and the development of scoring functions for additional targets.

01 Jan 2025·Microchemical Journal

Determination of 25 quinolones in water and milk by a magnetic sorbent Fe3O4@SiO2-HBTA-TTA-COF combining with UPLC-MS/MS

Author: Zhang, Hao ; Wang, Ke ; Li, Zhiwei ; Ma, Ling ; Ma, Weihao ; Nie, Jiayuan ; Qiang, Chunyu

In this study, a novel magnetic covalent organic framework (Fe₃O₄@SiO₂-HBTA-TTA-COF) was synthesized, which was fully characterized by SEM, transmission electron microscopy, etc.Furthermore, a new method was developed for the detection of 25 quinolones (QNs) in water and milk using the Fe3O4@SiO2-HBTA-TTA-COF as magnetic solid-phase extraction adsorbent coupled with ultra-performance liquid chromatoghy-tandem mass spectrometry (UPLC-MS/MS).Meanwhile, various exptl. parameters were optimized including sample solution pH, adsorbent dosage and extention time, etc.Under the optimal conditions, good linearity in the range of 0.1- 200μg.L^-1 (R²≥0.999) were obtained, the recoveries of 25 QNs were 70.04 -104.4 with the relative standard deviations lower than 9.87 (n = 5), the limits of detection were 0.003-0.010μg.L ^-1 for water and 0.018-0.722μg.kg^-1 for milk.This established method was high-sensitive and high-throughput, which can be used as a good alternative method for the selective determination of 25 QNs in water and milk.

01 Sep 2024·Congenital Anomalies

Pregnancy outcomes after first‐trimester exposure to fluoroquinolones: Findings based on an integrated database from two Japanese institutions

Article

Author: Takahashi, Kunihiko ; Yakuwa, Naho ; Yamane, Ritsuko ; Anzai, Tatsuhiko ; Murashima, Atsuko ; Goto, Mikako

AbstractGiven the paucity of safety data on fluoroquinolone antibiotics in pregnancy, a prospective observational cohort study was conducted in pregnant women who sought help and advice on drug use at two teratology information institutes in Japan. The primary endpoint of the study was the incidence of major congenital anomalies. The study population included pregnant women exposed to (i) fluoroquinolones (fluoroquinolone group), (ii) β‐lactams (infectious control group), or (iii) other agents considered to be nonteratogenic in humans (nonteratogenic control group) during the first trimester. The frequency of major congenital anomalies was compared across groups using a logistic regression model that adjusted for maternal age, smoking status, drinking status, facility consulted, and time of consultation. The fluoroquinolone group consisted of 411 women who had 383 children born alive. The infectious control and nonteratogenic control groups consisted of 1416 and 1482 women who had 1322 and 1401 children born alive, respectively. The incidence of major congenital anomalies was 1.5%, 2.0%, and 1.6% in the fluoroquinolone group, infectious control, and nonteratogenic control groups, respectively. Logistic regression showed that fluoroquinolone exposure is not a significant risk factor for major congenital anomalies. In conclusion, first‐trimester exposure to fluoroquinolone antibiotics was not associated with increased maternal or fetal risks.

100 Deals associated with Garenoxacin Mesilate Hydrate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Garenoxacin Mesilate Hydrate	J01MA19	DB06160

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Escherichia Coli Infections	Japan	Astellas Pharma, Inc.	31 Jul 2023
Escherichia Coli Infections	Japan	Taisho Pharmaceutical Co., Ltd.	31 Jul 2023
Klebsiella Infections	Japan	Taisho Pharmaceutical Co., Ltd.	31 Jul 2023
Klebsiella Infections	Japan	Astellas Pharma, Inc.	31 Jul 2023
Otitis Media	Japan	Taisho Pharmaceutical Co., Ltd.	31 Jul 2023
Otitis Media	Japan	Astellas Pharma, Inc.	31 Jul 2023
Pharyngolaryngitis	Japan	Taisho Pharmaceutical Co., Ltd.	31 Jul 2023
Pharyngolaryngitis	Japan	Astellas Pharma, Inc.	31 Jul 2023
Pneumococcal Infections	Japan	Astellas Pharma, Inc.	31 Jul 2023
Pneumococcal Infections	Japan	Taisho Pharmaceutical Co., Ltd.	31 Jul 2023
Pneumonia, Bacterial	China	FUJIFILM Toyama Chemical Co., Ltd.	25 Jul 2019
Respiratory Tract Infections	China	Toyama Chemical Co., Ltd.	12 Jul 2019
Bacterial Infections	South Korea	Dong-A ST Co., Ltd.	01 Sep 2009
Acute Bronchitis	Japan	FUJIFILM Toyama Chemical Co., Ltd.	31 Jul 2007
Laryngitis	Japan	FUJIFILM Toyama Chemical Co., Ltd.	31 Jul 2007
Pharyngitis	Japan	FUJIFILM Toyama Chemical Co., Ltd.	31 Jul 2007
Pneumonia	Japan	FUJIFILM Toyama Chemical Co., Ltd.	31 Jul 2007
respiratory tract; infection, chronic	Japan	FUJIFILM Toyama Chemical Co., Ltd.	31 Jul 2007
Sinusitis	Japan	FUJIFILM Toyama Chemical Co., Ltd.	31 Jul 2007
Tonsillitis	Japan	FUJIFILM Toyama Chemical Co., Ltd.	31 Jul 2007

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bronchitis, Chronic	Preclinical	European Union	Merck GmbH	-
Community Acquired Pneumonia	Preclinical	European Union	Merck GmbH	-
Complicated skin and soft tissue infection	Preclinical	European Union	Merck GmbH	-
Intraabdominal Infections	Preclinical	European Union	Merck GmbH	-